Lactate Dehydrogenase-to-Albumin Ratio and Adverse Outcomes in HFrEF/HFmrEF Patients

A retrospective cohort of 1,084 hospitalized patients with heart failure with reduced or mildly reduced ejection fraction, studied over a mean follow-up of 29.3 months. The dataset, authored by Yaping Zhang and last updated in 2026, investigates the association between the lactate dehydrogenase-to-albumin ratio (LAR) and adverse clinical outcomes.

Use Cases

• Training predictive models for heart failure readmission risk based on the LAR biomarker.
• Analyzing the non-linear relationship between LAR and all-cause mortality for clinical insights.
• Conducting sensitivity and subgroup analyses to validate biomarker robustness in heart failure cohorts.
• Assessing the incremental predictive value of a new biomarker using C-index, NRI, and IDI metrics.

Strengths

• Includes 1,084 patient records, providing a substantive cohort for analysis.
• Features a mean follow-up period of 29.3 months, enabling longitudinal outcome tracking.
• Analysis employed multiple statistical methods (Cox regression, Kaplan-Meier, Fine-Grey model) to assess associations.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale ML tasks.
• The dataset is very small at 20.4 KB, indicating limited scope and likely summary-level data.

Provenance

Source

Yaping Zhang via figshare.

Collection Method

Retrospective cohort study of hospitalized patients.

Time Range

Mean follow-up of 29.3 months; specific collection dates unknown.

Freshness

Last updated 2026-04-27 10:39:33; freshness should be verified.